LIST OF CONTENTS

NUMBER 1, JANUARY 1988

PROCEEDINGS OF THE 4th EORTC BREAST CANCER WORKING CONFERENCE

Editorial *R. D. Rubens* and *J. A. van Dongen*	1	**The 4th EORTC Breast Cancer Working Conference, London, 1-3 July 1987**
J. Wildiers, K. Vantongelen, J. A. van Dongen, N. Rotmensz, R. Sylvester and *the members of the Group*	3	**Activities of the EORTC Breast Cancer Co-operative Group: an overview**
M. Tubiana and *S. Koscielny*	9	**Cell kinetics, growth rate and the natural history of breast cancer. The Heuson Memorial Lecture**
R. D. Cardiff	15	**Cellular and molecular aspects of neoplastic progression in the mammary gland**
A. Howell and *R. R. Millis*	21	**Cellular aspects of breast cancer: workshop report**
T. J. A. Key and *M. C. Pike*	29	**The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer**
F. de Waard and *D. Y. Wang*	45	**Epidemiology and prevention: workshop report**
A. B. Miller	49	**Screening for breast cancer: a review**
N. E. Day and *J. Chamberlain*	55	**Screening for breast cancer: workshop report**
M. N. Maisey	61	**Imaging techniques in breast cancer. What is new? What is useful?—a review**
M. Colman and *W. Mattheiem*	69	**Imaging techniques in breast cancer: workshop report**
I. S. Fentiman	73	**Surgery in the management of early breast cancer: a review**
H. Bartelink	77	**Radiotherapy in the management of early breast cancer: a review**
R. D. Rubens	83	**Adjuvant systemic treatment for early breast cancer: a review**
E. van der Schueren and *J. A. van Dongen*	89	**Management of early stage breast cancer—current status of treatment: workshop report**
T. J. Powles	95	**Advanced breast cancer—new approaches to treatment: a review**
H. T. Mouridsen and *R. Paridaens*	99	**Advanced breast cancer—new approaches to treatment: workshop report**
EJCCO Service	i	
Software Survey Section	I	

NUMBER 2, FEBRUARY 1988

Perspectives and Commentaries *J. Klastersky*	107	**Therapy of small cell lung cancer: anything new?**
A. M. Goorin	113	**Adjuvant chemotherapy for osteogenic sarcoma**
A. Coune	117	**Amphotericin B as a potentiation agent to cytotoxic chemotherapy**
B. M. J. Cantwell, J. M. Bozzino, P. Corris and *A. L. Harris*	123	**The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer**
J. P. Kleisbauer, D. Vesco, J. Orehek, B. Blaive, C. Clary, R. Poirier, S. Saretto, P. Carles, G. Dongay, J. C. Guerin and *Y. Martinat*	131	**Treatment of brain metastases of lung cancer with high doses of etoposide (VP16-213). Cooperative study from the Groupe Français Pneumo-Cancérologie**
A.-M. Lebacq-Verheyden, A. Neirynck, A.-M. Ravoet, Y. Humblet, H. Oie, I. Linnoila, A. F. Gazdar, J. D. Minna and *M. Symann*	137	**Monoclonal antibodies for the *in vitro* detection of small cell lung cancer metastases in human bone marrow**
J.-L. Canon, Y. Humblet, A.-M. Lebacq-Verheyden, P. Manouvriez, H. Bazin, J. Rodhain, J. Prignot and *M. Symann*	147	**Immunodetection of small cell lung cancer metastases in bone marrow using three monoclonal antibodies**

R. Vukić, R. Tomek, F. Čulo and *M. Marušić*	151	**The effectiveness of intravenously administered immune lymphoid cells against intraperitoneally growing tumor correlates with their homing in the recipients' lymphoid organs**
C. Burtin, C. Noirot, P. Scheinmann, L. Galoppin, D. Sabolovic and *P. Bernard*	161	**Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine)**
L. Gailis, L. Dumas and *M. Page*	169	**Ambiguous effect of chlorpromazine on doxorubicin activity against P388D$_1$ tumours in mice**
J. Lankelma, M. Stuurman, J. van Hoogenhuijze, A. van Bochove, J. B. Vermorken, J. Verweij and *H. M. Pinedo*	175	**The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration**
P. F. Bruning, A. Halling, F. J. M. Hilgers, G. Kappner, E. K. Poelhuis, A. M. Kobashi-Schoot and *P. F. Schouwenburg*	181	**Postoperative nasogastric tube feeding in patients with head and neck cancer: a prospective assessment of nutritional status and well-being**
M. Ewertz, G. Schou and *J. D. Boice Jr*	189	**The joint effect of risk factors on endometrial cancer**
F. Lauria, R. Foà, D. Raspadori, P. L. Zinzani, M. Buzzi, M. T. Fierro, M. Bonferroni, R. Fanin, C. Gallizia, M. G. Michieli, G. Degani, L. Resegotti and *S. Tura*	195	**Treatment of hairy-cell leukaemia with α-interferon (α-IFN)**
S. Vest, E. Bork and *H. H. Hansen*	201	**A phase I evaluation of N^{10}-propargyl-5,8-dideazafolic acid**
B. C. Baguley and *G. J. Finlay*	205	**Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to Adriamycin-resistant P388 leukaemia cells**
B. C. Baguley, S. B. Calveley and *V. J. Harvey*	211	**Effects of CI-921, an analogue of amsacrine, on advanced Lewis lung tumours in mice: relevance to clinical trials**
D. R. Pledger, A. Belfield, J. H. Kennedy and *S. B. Kaye*	219	**Onco-developmental protein concentrations in the sera of patients with ovarian cancer prior to treatment**
W. R. Miller, A. A. Shivas, P. Franchimont and *D. E. Haagensen*	223	**Breast gross cystic disease protein 15 in human breast cancer in culture**
P. Boyle, M. Soukop, C. Scully, A. G. Robertson, H. J. G. Burns, C. R. Gillis and *S. B. Kaye*	229	**Improving prognosis of Hodgkin's disease in Scotland**
S. Tokudome, M. Ikeda, K. Matsushita, Y. Maeda and *M. Yoshinari*	235	**Hepatocellular carcinoma among HBsAg positive blood donors in Fukuoka, Japan**
B. E. Persson, E. Ståhle, L. Påhlman, B. Glimelius and *J. Holmgren*	241	**CA-50 as a tumour marker for monitoring colorectal cancer: antigen rises in patients postoperatively precede clinical manifestations of recurrence**
H. Roed, L. L. Vindeløv, I. J. Christensen, M. Spang-Thomsen and *H. H. Hansen*	247	**The cytotoxic activity of cisplatin, carboplatin and teniposide alone and combined determined on four human small cell lung cancer cell lines by the clonogenic assay**
M. van Glabbeke, J. Renard, H. M. Pinedo, F. Cavalli, J. Vermorken, C. Sessa, R. Abele, M. Clavel and *S. Monfardini*	255	**Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG)**
Clinical Trials Summaries		
R. A. Joss, S. Monfardini, M. Hansen, P. Dombernowsky, J. Renard and *H. M. Pinedo*	263	**Negative phase II trial of menogaril in advanced squamous, adeno- and large cell carcinoma of the lung**
Sounding Board		
C. B. H. W. Lamers and *J. B. M. J. Jansen*	267	**Role of gastrin and cholecystokinin in tumours of the gastrointestinal tract**
Letters to the Editor		
C. La Vecchia, A. Decarli and *C. Cislaghi*	275	**Changes in breast cancer mortality in Italy**
E. Campora, L. Repetto, P. Giuntini, G. Bertelli, D. Amoroso, M. R. Sertoli and *R. Rosso*	277	**LDH in the follow-up of stage I malignant melanoma**
A. de Rossi, F. Bortolotti, P. Cadrobbi and *L. Chieco-Bianchi*	279	**Trends of HTLV-I and HIV infections in drug addicts**
Special Article		
S. Raam	281	**International Research Group for Steroid Hormone Receptor Assays**

News from EORTC *B. W. Fox*	283	**New concepts in anticancer drug design**
International Symposium on Controversies in the Management of Differentiated Thyroid Cancer		
C. J. H. van de Velde, J. F. Hamming, B. M. Goslings, L. J. D. M. Schelfhout, O. H. Clark, S. Smeds, H. A. Bruining, E. P. Krenning and *B. Cady*	287	**Report of the consensus development conference on the management of differentiated thyroid cancer in the Netherlands**
S. Smeds and *S. Lennquist*	293	**The role of aspiration cytology in the management of thyroid nodules**
E. P. Krenning, L. Ausema, H. A. Bruining and *G. Hennemann*	299	**Clinical and radio-diagnostic aspects in the evaluation of thyroid nodules with respect to thyroid cancer**
O. H. Clark, K. Levin, Q.-H. Zeng, F. S. Greenspan and *A. Siperstein*	305	**Thyroid cancer: the case for total thyroidectomy**
J. N. Attie	315	**Modified neck dissection in treatment of thyroid cancer: a safe procedure**
J. F. Hamming, C. J. H. van de Velde, G. J. Fleuren and *B. M. Goslings*	325	**Differentiated thyroid cancer: a stage adapted approach to the treatment of regional lymph node metastases**
L. J. D. M. Schelfhout, C. L. Creutzberg, J. F. Hamming, G. J. Fleuren, D. Smeenk, J. Hermans, C. J. H. van de Velde and *B. M. Goslings*	331	**Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor**
A. W. G. Goolden	339	**The use of radioactive iodine in thyroid carcinoma**
M. Schlumberger, J. P. Travagli, P. Fragu, P. Gardet, J. Lumbroso and *C. Parmentier*	345	**Follow-up of patients with differentiated thyroid carcinoma. Experience at Institut Gustave-Roussy, Villejuif**
Books Received	351	
EJCCO Service	i	
Software Survey Section	I	

NUMBER 3, MARCH 1988

Perspectives and Commentaries *R. Feld, G. Deboer* and *U. Sagman*	353	**Prognostic factors for small cell carcinoma of the lung**
M. S. Aapro and *J. B. Vermorken*	357	**Potential of colony-forming cell assays in the evaluation of ovarian cancer**
M. I. Sherman and *G. A. Truitt*	359	**Prevention and therapy of tumors with arotinoids**
D. J. Gross, E. Simon, L. Szwarc-Bilotynski, E. Margalioth and *J. Gross*	363	**An immunochemical assay for natural IgM antibodies with an affinity to galactose and whose titer is reduced in the sera of cancer patients**
V. Barnaba, G. Valesini, G. Gattamelata, R. Benvenuto, A. Velardi and *F. Balsano*	369	**Increased number of CD4 cells able to bind to natural killer cell targets in the peripheral blood of AIDS related complex patients**
J. Andersen, S. M. Bentzen and *H. S. Poulsen*	377	**Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation**
L. Madeddu, N. Legros, N. Devleeschouwer, C. Bosman, M. J. Piccart and *G. Leclercq*	385	**Estrogen receptor status and estradiol sensitivity of MCF-7 cells in exponential growth phase**
E. M. Ibrahim, M. B. Satti, H. Y. Al-Idrissi, F. A. Al-Mulhim, G. H. Abssod and A. AbdelJabar	391	**Non-Hodgkin's lymphoma in Saudi Arabia: prognostic factors and an analysis of the outcome of combination chemotherapy only, for both localized and advanced disease**
N. M. Mokhtar, A. A. El-Aaser, M. N. El-Bolkainy, H. A. Ibrahim, N. B. El-Din and *N. Z. Moharram*	403	**Effect of soybean feeding on experimental carcinogenesis—III. Carcinogenecity of nitrite and dibutylamine in mice: a histopathological study**
P.-E. Jönsson, C. Ingvar, M. Fernö, L. Hafström and *C.-M. Rudenstam*	413	**Phase II study of estramustine phosphate (Estracyt®) in patients with metastatic melanoma**

P. H. B. Willemse, L. D. Dikkeschei, N. H. Mulder, E. van der Ploeg, D. Th. Sleijfer and *E. G. E. de Vries*	417	**Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer**
F. Pannuti, A. Martoni, G. Cilenti, C. M. Camaggi, F. Fruet and other investigators	423	**Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients**
K. Aabo, M. Kjaer and *H. H. Hansen*	431	**High-dose ketoconazole to untreated stage D prostate cancer**
C. Kamby, C. Rose, B. Ejlertsen, J. Andersen, N. E. Birkler, L. Rytter, K. W. Andersen and *K. Zedeler*	439	**Adjuvant systemic treatment and the pattern of recurrences in patients with breast cancer**
R. N. Hitchins, D. H. Harman, R. A. Davey and *D. R. Bell*	449	**Identification of a multidrug resistance associated antigen (P-glycoprotein) in normal human tissues**
G. P. M. ten Velde, B. Schutte, A. Vermeulen, A. Volovics, M. M. J. Reynders and *G. H. Blijham*	455	**Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer**
J. Y. Bounaud, M. P. Bounaud, T. Metayer and *F. Begon*	461	**Breast cancer estrogen receptor assays: assessment of a direct hyperbolic fitting to analyse multipoint binding data**
M. H. N. Tattersall, A. O. Langlands, J. S. Simpson and *J. F. Forbes*	467	**Undergraduate education about cancer: a survey in Australian medical schools**
J. Carmo-Pereira, F. O. Costa, E. Henriques, M. G. Cantinho-Lopes, F. Godinho and *A. Sales-Luis*	473	**Primary chemotherapy with mitoxantrone and prednisone in advanced breast carcinoma. A phase II study**
K. Mattson, L. R. Holsti, P. Holsti, M. Jakobsson, M. Kajanti, K. Liippo, M. Mäntylä, S. Niitamo-Korhonen, V. Nikkanen, E. Nordman, L.-H. Platin, S. Pyrhönen, M.-L. Romppanen, R. Salmi, L. Tammilehto and *P. J. Taskinen*	477	**Inoperable non-small cell lung cancer: radiation with or without chemotherapy**
P. C. Huijgens, G. J. Ossenkoppele, J. van der Lelie, L. L. M. Thomas, M. J. Wijngaarden and *R. M. R. Reijneke*	483	**Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma**
Sounding Board *N. Cascinelli, M. Greco* and *E. Leo*	487	**Comments on primary and adjuvant treatments of breast cancer**
Letters to the Editor *U. Tirelli* et al.	493	
N. Taleb, N. Geahchan, M. Ghosn, E. Brihi and *P. Sacre*	495	**Vulvar pruritus after high-dose dexamethasone**
J. Ishihara, N. Saijo, F. Kanzawa, Y. Matsushima, Y. Sasaki, H. Takahashi, H. Nakano, K. Nakagawa, W. S. Hong, A. Hoshi and *T. Takahashi*	497	**Augmentation of colony formation of cultured cell lines by pleural effusion from patients with lung cancer**
C. A. Rubio	499	**Post-carcinogen interval in carcinogenesis**
L. N. Owen and *A. G. Owen*	501	**Pilot studies on the effects of a phosphomolybdic tungstic acid compound (PTMC) on spontaneous malignant tumours in dogs**
S. G. Allan, A. J. Cheyne, P. S. Warrington and *M. A. Cornbleet*	503	**Emesis and cancer chemotherapy**
Papers in Honor of Dr. Yvon Kenis *H. J. Tagnon*	507	**Address in honor of Dr. Yvon Kenis**
A. Borkowski, J. J. Body and *G. Leclercq*	509	**Hormone receptors and cancer**
J. P. Sculier, F. Ries, N. Verboven, A. Coune and *J. Klastersky*	513	**Role of intensive care unit in a medical oncology department**
J. P. Sculier, J. Klastersky, D. Becquart, G. Vandermoten, P. van Houtte, P. Rocmans, J. Thiriaux, E. Longeval, P. Ravez, P. Libert, A. Flemalle, J. Michel, M. Mairesse, P. Mommen and *O. Dalesio*	519	**Phase II study of an intensive combination chemotherapy with cisplatin, adriamycin, etoposide and cyclophosphamide (CAVE) in small cell lung cancer**

J.-P. Sculier, A. Coune, F. Meunier, C. Brassinne, C. Laduron, C. Hollaert, N. Collette, C. Heymans and *J. Klastersky*	527	**Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections**
F. Meunier and *J. Klastersky*	539	**Recent developments in prophylaxis and therapy of invasive fungal infections in granulocytopenic cancer patients**
P. E. G. Kristjansen and *H. H. Hansen*	545	**Brain metastases from small cell lung cancer treated with combination chemotherapy**
M. Vandeputte and *H. Sobis*	551	**Experimental rat model for human yolk sac tumor**
P. Alberto, B. Mermillod, G. Germano, S. Kaplan, W. Weber, R. Joss, B. Spati, G. Martz and *F. Cavalli*	559	**A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma**
P. Alberto, W. F. Jungi, P. Siegenthaler, B. Mermillod, J. P. Obrecht, G. Decoster and *F. Cavalli*	565	**A phase II study of doxifluridine in patients with advanced breast cancer**
E. Boven, B. Winograd, Ø. Fodstad, M. W. Lobbezoo and *H. M. Pinedo*	567	**Preclinical phase II studies in human tumor lines: a European multicenter study**
EJCCO Service	i	
Software Survey Section	I	

NUMBER 4, APRIL 1988

Acknowledgements	575	
Perspectives and Commentaries		
J. Cummings and *J. F. Smyth*	579	**Pharmacology of Adriamycin: the message to the clinician**
W. W. ten Bokkel Huinink	583	**Current status of chemotherapy for ovarian carcinoma**
J. H. Goldie	587	**Mathematical models to predict behaviour of tumours?**
L. R. Ferguson and *P. M. Turner*	591	**'Petite' mutagenesis by anticancer drugs in *Saccharomyces cerevisiae***
D. Beccati, N. Grilli, P. Schincaglia, C. Naldoni, L. Tavolazzi, R. Ranaldi, L. Dogliotti, M. Torta and *A. Angeli*	597	**Apocrine cells in breast cyst fluid and their relationship to cyst type: a morphometric study**
J. C. Norman, J. R. Puddefoot, E. Anderson and *H. Braunsberg*	603	**Relationships between polyamine, deoxyribonucleic acid and oestrogen receptor binding site concentrations in human breast tumours**
H. Haaxma-Reiche and *S. Daenen*	615	**Acute lymphoblastic leukemia in adults: results of intraventricular maintenance chemotherapy for central nervous system prophylaxis and treatment**
W. J. F. van der Vijgh, F. Elferink, J. B. Vermorken, W. W. ten Bokkel Huinink, I. Klein, H. E. Gall, G. Simonetti, J. G. McVie and *H. M. Pinedo*	621	**Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua(1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum(II) (spiroplatin) during a phase I trial**
G. Giaccone, M. Donadio, G. M. Bonardi, F. Testore and *A. Calciati*	629	**Teniposide (VM26): an effective treatment for brain metastases of small cell carcinoma of the lung**
E. Marcuello, E. Alba, G. Gómez de Segura, M. Sánchez Parra, L. de Andrés, A. López Pousa, C. Pallares, J. R. Germá and *J. J. López López*	633	**Cisplatin and intravenous continuous infusion of bleomycin in advanced and metastatic esophageal cancer**
R. Gerritsen van der Hoop, P. de Koning, E. Boven, J. P. Neijt, F. G. I. Jennekens and *W. H. Gispen*	637	**Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats**
Y. Koga, K. Sugimachi, H. Kuwano, M. Mori and *H. Matsufuji*	643	**Cytophotometric DNA analysis of esophageal dysplasia and carcinoma induced in rats by *N*-methyl-*N*-amylnitrosamine**
C. Caldani, A. Thyss, M. Schneider, G. Milano, L. Buray and *F. Demard*	653	**Orosomucoid:prealbumin ratio—a marker of the host–tumor relationship in head and neck cancer**

A. Dupont, F. Labrie, M. Giguere, J.-P. Borsanyi, Y. Lacourciere, N. Bergeron, L. Cusan, A. Belanger and *J. Emond*	659	**Combination therapy with flutamide and [D-Trp^6]LHRH ethylamide for stage C prostatic carcinoma**
P. A. J. Speth, R. A. P. Raijmakers, J. B. M. Boezeman, P. C. M. Linssen, T. J. M. de Witte, H. M. C. Wessels and *C. Haanen*	667	***In vivo* cellular adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells**
P. O. M. Mulder, E. G. E. de Vries, H. S. Koops, T. Splinter, A. Maas, S. van der Geest, N. H. Mulder and *D. Th. Sleijfer*	675	**Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors**
T. Chisesi, G. Capnist, E. de Dominicis and *E. Dini*	681	**A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma**
D. Cunningham, C. J. Bradley, G. J. Forrest, A. W. Hutcheon, L. Adams, M. Sneddon, M. Harding, D. J. Kerr, M. Soukop and *S. B. Kaye*	685	**A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues**
S. Kaasa, A. Mastekaasa, I. Stokke and *S. Naess*	691	**Validation of a quality of life questionnaire for use in clinical trials for treatment of patients with inoperable lung cancer**
John M. Kaldor, N. E. Day and *K. Hemminki*	703	**Quantifying the carcinogenicity of antineoplastic drugs**
V. Hug, H. D. Thames, Jr., A. Polyzos and *D. Johnston*	713	**Chemoresistance is not a cause of the apparent failure of adjuvant chemotherapy in postmenopausal women**
L. V. A. M. Beex, M. A. Mackenzie, J. M. M. Raemaekers, A. G. H. Smals, Th. J. Benraad, P. W. C. Kloppenborg and the Breast Cancer Study Group	719	**Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour**
E. A. Abdi	723	**Combination of interferon and prednisone in human cancer**
S. Mitrani-Rosenbaum, D. Gal, M. Friedman, N. Kitron, R. Tsvieli, N. Mordel and *S. O. Anteby*	725	**Papillomaviruses in lesions of the lower genital tract in Israeli patients**
B. M. J. Cantwell, V. Macaulay, A. L. Harris, S. B. Kaye, I. E. Smith, R. A. V. Milsted and *A. H. Calvert*	733	**Phase II study of the antifolate N^{10}-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer**
J. Lindgren, P. Kuusela, P.-E. Hellström, T. Pettersson and *M. Klockars*	737	**The ovarian cancer associated antigen CA 125 in patients with pleural effusions**
W. P. van Lawick van Pabst, B. L. A. M. Langenhorst, P. G. H. Mulder, R. L. Marquet and *J. Jeekel*	741	**Effect of perioperative blood loss and perioperative blood transfusions on colorectal cancer survival**
A. Niiranen	749	**Long-term survival in small cell carcinoma of the lung**
P. E. Postmus, L. de Ley, A. Y. van der Veen, G. Mesander, C. H. C. M. Buys and *J. D. Elema*	753	**Two small cell lung cancer cell lines established from rigid bronchoscope biopsies**
A. van der Gaast, J. Verweij, A. S. Th. Planting and *G. Stoter*	765	**5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary**
C. Sessa, M. Zucchetti, M. Ginier, Y. Willems, M. D'Incalci and *F. Cavalli*	769	**Phase I study of the antifolate N^{10}-propargyl-5,8-dideazafolic acid, CB 3717**
O. K. Schlappack, C. Bush, J. I. Delic and *G. G. Steel*	777	**Growth and chemotherapy of a human germ-cell tumour line (GCT 27)**
G. J. S. Rustin, S. Dische, S. T. de Garis and *A. Nelstrop*	783	**Treatment of advanced malignant melanoma with interferon alpha and etretinate**
R. Valavaara, S. Pyrhönen, M. Heikkinen, P. Rissanen, G. Blanco, E. Thölix, E. Nordman, P. Taskinen, L. Holsti and *A. Hajba*	785	**Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study**
C. J. H. van de Velde and *L. M. de Brauw*	791	**Attitudes towards detection and management of hepatic metastases in the Western world**
Clinical Trials Summaries		
J. Verweij, J. Alexieva-Figusch, M. F. de Boer, B. Reichgelt and *G. Stoter*	795	**Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group**
Letters to the Editor		
W. C. T. Shiu and *S. Y. Tsao*	797	**Etoposide (VP16-213) in the treatment of advanced nasopharyngeal carcinoma**

T. Abe, H. Yashige, J. Inazawa, S. Yokota, S. Tsuda, M. Taniwaki, S. Takeda, S. Misawa and *T. Takino*	799	**The use of Diamox in the sequential methotrexate–5-fluorouracil therapy of advanced gastrointestinal cancer**
J. Greidanus, P. H. B. Willemse, D. Th. Sleijfer, N. H. Mulder, R. C. J. Verschueren, R. Nieweg and *E. G. de Vries*	801	**Phase II study of a 21-day continuous infusion schedule with epirubicin in metastatic colorectal cancer**
H. Nagasawa and *R. Konishi*	803	**Stimulation by caffeine of spontaneous mammary tumorigenesis in mice**
Reply to Comments *E. Robinson*	807	
Announcement	809	
EJCCO Service	i	
Software Survey Section	I	

NUMBER 5, MAY 1988

H. J. Tagnon	811	**Looking back...**
Perspectives and Commentaries *C. P. Delcour* and *J. L. Struyven*	815	**Interventional radiology in oncology**
R. S. Verma, M. J. Macera and *A. Babu*	821	**The role of heterochromatin in the origin of isochromosome 1 in neoplastic cells**
D. N. Carney and *M. Teeling*	825	**Neuron-specific enolase: how useful as a cancer marker?**
Y. Aotsuka and *H. Hagiwara*	829	**Identification of a malignant cell associated antigen recognized by a human monoclonal antibody**
G. Shklar and *J. Schwartz*	839	**Tumor necrosis factor in experimental cancer regression with alphatocopherol, beta-carotene, canthaxanthin and algae extract**
S. Sekiya, T. Oosaki, S. Andoh, N. Suzuki, K. Nagao and *H. Takamizawa*	851	**The isolation and characterization of cisplatin-resistant rat ovarian cancer cells**
S. Chaitchik, M. Deutsch, O. Asher, G. Krauss, P. Lebovich, H. Michlin and *A. Weinreb*	861	**An evaluation of the SCM test for the diagnosis of cancer of the breast**
G. Secreto, C. Recchione, M. Zambetti, G. Fariselli and *P. Ballerini*	867	**Hormonal changes induced by the pure antiandrogen flutamide in postmenopausal women with advanced breast cancer**
M. Danova, A. Riccardi, P. Gaetani, G. D. Wilson, G. Mazzini, S. Brugnatelli, R. Buttini, G. Butti, G. Ucci, P. Paoletti and *E. Ascari*	873	**Cell kinetics of human brain tumors: *in vivo* study with bromodeoxyuridine and flow cytometry**
P. Hannequin, J. C. Liehn, B. Maes and *M. J. Delisle*	881	**Multivariate analysis in solitary cold thyroid nodules for the diagnosis of malignancy**
P. E. Postmus, N. H. Mulder and *J. D. Elema*	889	**Graft versus host disease after transfusions of non-irradiated blood cells in patients having received autologous bone marrow**
N. Terada, H. Wakimoto, R. Yamamoto, N. Uchida, D. Takatsuka, T. Takada, H. Taniguchi, W. Li, Y. Kitamura and *K. Matsumoto*	895	**Increase in collagen production with loss of androgen responsiveness in cultured androgen-responsive Shionogi carcinoma 115 cells**
S. J. Kellie, J. de Kraker, J. S. Lilleyman, A. Bowman and *J. Pritchard*	903	**Ifosfamide in previously untreated disseminated neuroblastoma**
P. Mack, B. Jeppsson, D. Widlus, I. Hägerstrand and *S. Bengmark*	909	**Combined intermittent dearterialization and intraperitoneal 5-fluorouracil administration for liver tumours in the rat**
H. H. Berendsen, L. de Leij, S. Poppema, P. E. Postmus, H. J. Sluiter and *H. The*	915	**Simultaneous standard light microscopy and immunohistology on bronchoscopically procured lung cancer specimens**
F. Farinati, D. Nitti, F. Cardin, F. di Mario, F. Costa, C. Rossi, A. Marchett, M. Lise and *R. Naccarato*	923	**CA 19-9 determination in gastric juice: role in identifying gastric cancer and high risk patients**

B. W. Hancock, L. Bruce, R. J. Sokol and *A. Clark*	929	**Transfer factor in Hodgkin's disease: a randomized clinical and immunological study**
J. Cassidy, M. V. Merrick, J. F. Smyth and *R. C. F. Leonard*	935	**Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography**
Sounding Board *A. C. Botti, G. R. Diamond* and *R. S. Verma*	939	**Lymphoma and acquired immunodeficiency syndrome: cytogenetic and molecular correlates**
Books Received	943	
EJCCO Service	i	
Software Survey Section	I	

NUMBER 6, JUNE 1988

D. W. van Bekkum and *H. B. Kal*	945	**Symposium in honour of Prof. L. M. van Putten on 'Preclinical Evaluation of Anti-cancer Drugs' and workshop on 'Experimental Models for Non-small Cell Bronchial Cancers' on the occasion of his retirement from the Radiobiological Institute TNO at Rijswijk, The Netherlands**
Perspectives and Commentaries *F. Ries*	951	**Nephrotoxicity of chemotherapy**
M. L'Hermite and *M. L'Hermite-Baleriaux*	955	**Prolactin and breast cancer**
F. Cavalli	959	**Ifosfamide: an old drug recently rediscovered**
E. Tueni, J.-P. Sculier and *J. Klastersky*	963	**Phase I study of a carboplatin–etoposide combination in advanced thoracic cancer**
A. Jakobsen, P. Bichel, G. B. Kristensen and *M. Nyland*	969	**Prognostic influence of ploidy level and histopathologic differentiation in cervical carcinoma stage Ib**
A. Azzarelli, V. Mazzaferro, V. Quagliuolo, R. A. Audisio, G. Colella, G. Bandieramonte, G. Dossena and *L. Gennari*	973	**Kaposi's sarcoma: malignant tumor or proliferative disorder?**
H. F. Dalske and *K. Hardy*	979	**Effect of low-dose doxorubicin on calcium content and norepinephrine response in rat aorta**
I. R. MacGregor and *W. R. Miller*	985	**Urokinase and tissue-type plasminogen activators are present in breast cyst fluids**
M. G. Lihou, P. J. Smith and *P. G. Parsons*	991	**Sensitivity of human neuroblastoma to activated dacarbazine: relationships between cell survival, methyltransferase activity and activation of adenovirus-5**
H. B. Kal and *D. W. van Bekkum*	999	**Comparison of chemosensitivity of transplantable non-small cell bronchial tumours of rats in syngeneic hosts and in nude rodents**
F. Pavesi, M. Lotzniker, P. Cremaschi, L. Marbello, L. Acquistapace and *R. Moratti*	1005	**Detection of malignant pleural effusions by tumor marker evaluation**
P. Schlag, J. Dörsam, J. L. A. Aguiar, R. Bartkowski and *M. Berger*	1013	**Hepatic arterial infusion (HAI) chemotherapy proves to be advantageous in the treatment of experimental liver tumors**
P. Dodion, D. de Valeriola, N. Crespeigne, B. Peeters, F. Wery, C. van Berchem, M. Piccart, E. Tueni, J. Joggi and *Y. Kenis*	1019	**Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days**
E. Petru, M. R. Berger, W. J. Zeller and *M. Kaufmann*	1027	***In vitro* evaluation of an estradiol-linked nitrosourea in mammary carcinomas of mouse, rat and man**
E. Bork, M. Hansen, P. Urdal, E. Paus, J. J. Holst, S. Schifter, M. Fenger and *F. Engbaek*	1033	**Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide**
L. Pedersen, I. Balslev, B. Guldhammer and *C. Rose*	1039	**Repeated fine needle aspirations in the diagnosis of soft tissue metastases in breast cancer**

R. N. Hitchins, L. Holden, E. S. Newlands, R. H. J. Begent, G. J. S. Rustin and *K. D. Bagshawe*	1041	**Single agent etoposide in gestational trophoblastic tumours**
P. J. M. Bakker, S. A. Danner, J. M. A. Lange and *K. H. N. Veenhof*	1047	**Etoposide for epidemic Kaposi's sarcoma: a phase II study**
D. Y. Wang, C. I. Mockridge, V. E. Fantl, B. de Stavola, D. S. Allen, B. S. Thomas, J. W. Moore, R. D. Bulbrook, I. H. Gravelle, H. G. Kwa, I. S. Fentiman and *J. L. Hayward*	1049	**Urinary epidermal growth factor excretion and breast cancer risk**
A. Ozaki, H. Nakano, K. Minato, K. Nakagawa, Y. Sasaki and *N. Saijo*	1055	**The difference in surface phenotypes between cytotoxic lymphocytes induced *in vivo* by systemic administration of human recombinant interleukin-2 and lymphokine activated killer cells induced *in vitro***
D. Peest, H. Deicher, R. Coldewey, H.-J. Schmoll and *I. Schedel*	1061	**Induction and maintenance therapy in multiple myeloma; a multicenter trial of MP versus VCMP**
A. M. Hendrick, M. D. Mitchell and *A. L. Harris*	1069	**Plasma prostaglandins in lung cancer**
Clinical Trials Summaries		
Z. Pastran, T. le Chevalier, P. Baldeyrou, M. Spielmann, R. Arriagada, J.-P. Droz and *J. Rouesse*	1073	**Phase II study of high dose ifosfamide plus mesna in inoperable non small cell lung carcinoma**
Letter to the Editor		
L. M. Cobb	1075	**Possible therapeutic use of modified anaerobic bacteria in cancer**
A. M. Stift and *H. J. Tagnon*	1079	**Report on the activities of the EORTC-NCI exchange program**
EJCCO Service	i	
Software Survey Section	I	

NUMBER 7, JULY 1988

Perspectives in Cancer Research		
Y. Touitou and *A. Bogdan*	1083	**Tumor markers in non-malignant diseases**
Perspectives and Commentaries		
H. Bleiberg	1093	**Identification of preneoplastic changes**
J. Hildebrand	1097	**Chemotherapy of brain metastases**
H. J. Harmsen Jr and *A. J. Porsius*	1099	**Endocrine therapy of breast cancer**
D. Brumioul, M. Lemaître, H. Barbason and *W. G. Verly*	1117	**Action of phenobarbital given to rats together with diethylnitrosamine on the O^6-ethylguanine content of liver DNA**
R. Danesi, A. Paparelli, N. Bernardini and *M. Del Tacca*	1123	**Cytofluorescence localization and disposition of doxorubicin and doxorubicinol in rat cardiac tissue**
B. Blöchl-Daum, H. G. Eichler, H. Rainer, R. Jakesz, H. Salzer, G. Steger, J. Schüller, E. Günther, B. Proksch and *G. Ehninger*	1133	**Escalating dose regimen of intraperitoneal mitoxantrone: phase I study—clinical and pharmacokinetic evaluation**
K. Herholz, P. Ziffling, W. Staffen, G. Pawlik, R. Wagner, K. Wienhard and *W.-D. Heiss*	1139	**Uncoupling of hexose transport and phosphorylation in human gliomas demonstrated by PET**
P. Gaglia, B. Caldarola, R. Bussone, F. Potente, D. Lauro, A. Jayme and *L. Caldarola*	1151	**Prognostic value of CEA and ferritin assay in breast cancer: a multivariate analysis**
P. Gauduchon, E. Bar, J.-P. Malas, M. Aubert, F. Sichel and *J.-Y. Le Talaër*	1157	**Serum galactosyltransferase activity with three acceptors in ovarian cancer patients**
S. M. Thorpe and *C. Rose*	1163	**Biological and clinical relevance of K_d values for estradiol binding in primary breast cancer tumors**
Y. J. Abul-Hajj, J. H. H. Thijssen and *M. A. Blankenstein*	1171	**Metabolism of estradiol by human breast cancer**
N. Christeff, C. Michon, G. Goertz, J. Hassid, S. Matheron, P. M. Girard, J. P. Coulaud and *E. A. Nunez*	1179	**Abnormal free fatty acids and cortisol concentrations in the serum of AIDS patients**
Y. Kikuchi, I. Kizawa, K. Oomori, I. Iwano, T. Kita, M. Miyauchi and *K. Kato*	1185	**Effects of cimetidine on interleukin-2 production by peripheral blood lymphocytes in advanced ovarian carcinoma**

P. Lagarde, H. Eghbali, F. Bonichon, I. de Mascarel, J. Chauvergne and *B. Hœrni*	1191	**Brief chemotherapy associated with extended field radiotherapy in Hodgkin's disease. Long-term results in a series of 102 patients with clinical stages I–IIIA**
M. Maeta, S. Koga, N. Shimizu, R. Hamazoe, A. Murakami, M. Ishiguro and *T. Sawada*	1199	**Intra-hepato-arterial chemotherapy with CDDP and 5-FU for metastases to the liver from colorectal and gastric cancers**
K. Teelmann and *W. Bollag*	1205	**Therapeutic effect of the arotinoid Ro 15-0778 on chemically induced rat mammary carcinoma**
R. E. Coleman, G. Mashiter, I. Fogelman, K. D. Whitaker, M. Caleffi, D. W. Moss and *R. D. Rubens*	1211	**Osteocalcin: a potential marker of metastatic bone disease and response to treatment**
J. Carmichael, J. G. Park, W. G. Degraff, J. Gamson, A. F. Gazdar and *J. B. Mitchell*	1219	**Radiation sensitivity and study of glutathione and related enzymes in human colorectal cancer cell lines**
D. Y. Wang, B. L. de Stavola, R. D. Bulbrook, D. S. Allen, H. G. Kwa, A. A. Verstraeten, J. W. Moore, I. S. Fentiman, J. L. Hayward and *I. H. Gravelle*	1225	**The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women**
P. Peltomäki, N. O. Bianchi, S. Knuutila, L. Teerenhovi, E. Elonen, R. Leskinen and *A. de la Chapelle*	1233	**Immunoglobulin kappa and lambda light chain dual genotype rearrangement in a patient with kappa-secreting B-CLL**
Letters to the Editor		
M. Menna-Perper, R. J. Lewis and *P. Manowitz*	1239	**High plasma free tryptophan levels as a possible promoter of cancer growth**
V. M. Macaulay, J. D. Teale, M. J. Everard, G. P. Joshi, J. L. Millar and *I. E. Smith*	1241	**Serum insulin-like growth factor-I levels in patients with small cell lung cancer**
Special Article		
F. Pannuti	1243	**International Symposium on Hormone Therapy in Oncology**
EJCCO Service	i	
Software Survey Section	I	

NUMBER 8, AUGUST 1988

Perspectives and Commentaries		
V. C. Jordan	1245	**The control of hormone-dependent breast cancer growth—are we talking about estrogen alone?**
C. Grégoire	1249	**Thymus and immunity—I. Early thymus research**
J. F. A. P. Miller	1257	**Thymus and immunity—II. The last three decades**
S. M. Thorpe, H. S. Poulsen, K. O. Pedersen and *C. Rose*	1263	**Impact of standardization of estrogen and progesterone receptor assays of breast cancer biopsies in Denmark**
H. Samonigg, D. K. Hossfeld, J. Spehn, H. Fill and *G. Leb*	1271	**Aclarubicin in advanced thyroid cancer: a phase II study**
M. Mottolese, I. Venturo, R. P. Donnorso, C. G. Curcio, M. Rinaldi and *P. G. Natali*	1277	**Use of selected combinations of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin**
Y. Asano, S. Okamura, T. Shibuya, E. Morioka, S. Taniguchi, M. Harada and *Y. Niho*	1285	**Effect of human G-CSF on clonogenic cells in acute myeloblastic leukemia**
J. Robert, M. David, S. Huet and *J. Chauvergne*	1289	**Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients**
P. Opat, J. Drbal, Z. Tauer and *R. Wotke*	1295	**Alteration of beta-2-microglobulin level in malignant lymphoproliferative diseases after a high dose of alpha-2-recombinant interferon**
I. S. Fentiman, F. R. Balkwill, B. S. Thomas, M. J. Russell, I. Todd and *G. F. Bottazzo*	1299	**An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer**
Ludwig Breast Cancer Study Group	1305	**On the safety of perioperative adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in breast cancer**
W. A. Schroyens, J. B. Meeker, P. Dodion, P. A. Stryckmans and *M. Rozencweig*	1309	**Comparative effect of cisplatin, spiroplatin, carboplatin, iproplatin and JM40 in a human myeloid clonogenic assay**

P. Stravoravdi and *M. Polyzonis*	1313	**The effect of bromocriptine on the lactotroph cells in two inbred strains of mice C_3H/Sy and AKR/Sy**
R. Dolcetti, V. De Re, A. Viel, M. Pistello, M. Tavian and *M. Boiocchi*	1321	**Nuclear oncogene amplification or rearrangement is not involved in human colorectal malignancies**
The Anglo-Egyptian Health Agreement Collaborative Study	1329	**Serum hormone levels in breast cancer patients and controls in Egypt and Great Britain**
A. Economidou-Karaoglou, M. Opsomer, G. Petit, M. Lans, H. S. Taper and *M. B. Robertfroid*	1337	**Characteristic variations of serum alkaline DNase activity in relation to response to therapy and tumor prognosis in human lung cancer**
M. Clavel, S. Monfardini, S. Gundersen, S. Kaye, P. Siegenthaler, J. Renard, M. van Glabbeke and *H. M. Pinedo*	1345	**Phase II study of iproplatin (CHIP, JM-9) in advanced testicular cancers progressing after prior chemotherapy**
A. Manni, B. Badger, C. Wright, J. Glenn, S. R. Ahmed and *L. M. Demers*	1349	**Species-specificity of estradiol regulated growth factors in breast cancer**
J. A. Double, M. C. Bibby, P. M. Loadman and *J. C. Bloomer*	1355	**Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations**
M. C. Bibby, J. A. Double and *C. M. Morris*	1361	**Anti-tumour activity of TCNU in a panel of transplantable murine colon tumours**
R. M. Phillips, M. C. Bibby and *J. A. Double*	1365	***In vitro* and *in vivo* responses of a panel of murine colon tumours to TCNU: a positive correlation**
M. A. Burton, B. N. Gray and *A. Coletti*	1373	**Effect of angiotensin II on blood flow in the transplanted sheep squamous cell carcinoma**
Clinical Trials Summaries		
P. Dombernowsky, M. Clavel, J. F. Smyth, A. Howell, M. van Glabekke, J. Renard and *H. M. Pinedo*	1377	**Phase II study of TCNU in advanced breast cancer**
A. T. van Oosterom, M. S. Aapro, F. Carnino, M. E. L. van der Burg, S. Pecorelli, N. Rotmensz, O. Dalesio and *J. B. Vermorken*	1379	**Esorubicin in advanced ovarian epithelial cancer**
Letters to the Editor		
C. Redman, M. G. Bradgate, T. P. Rollason, C. J. Hilton and *A. Williams*	1381	**Cancer antigen CA125 in epithelial ovarian cancer: immunohistochemical expression before and after chemotherapy**
L. D. de Haan, P. H. M. de Mulder, L. V. A. M. Beex, F. M. J. Debruyne, T. Challoner and *B. E. de Pauw*	1383	**The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 ($5\text{-}HT_3$) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting**
Special Article		
J. A. Hickman	1385	**Membrane targets in cancer chemotherapy**
EJCCO Service	i	
Software Survey Section	I	

NUMBER 9, SEPTEMBER 1988

G. Santelli, G. Melillo, A. Marfella, M. Napolitano, V. D'Alessio, R. A. Satriano, E. Beth-Giraldo, G. Giraldo, M. Perna and *G. Castello*	1391	**Urinary neopterin and immunological features in patients with Kaposi's sarcoma**
R. Whelan, E. Gibby, D. Sheer, S. Povey and *B. T. Hill*	1397	**Characterization of a continuous cell line in culture established from a Krukenberg tumour of the ovary arising from a primary gastric adenocarcinoma**
M. Bontenbal, P. Sonneveld, J. A. Foekens and *J. G. M. Klijn*	1409	**Oestradiol enhances doxorubicin uptake and cytotoxicity in human breast cancer cells (MCF-7)**
J. M. S. van Maanen, E. van den Akker, J. de Vries, T. R. J. Bakkenist, J. Lankelma, J. Retèl and *H. M. Pinedo*	1415	**Structure–bioactivation relationship of a series of podophyllotoxin derivatives**
T. Wada, T. Akiyoshi and *Y. Nakamura*	1421	**A simplified tritiated thymidine incorporation assay for chemosensitivity testing of human tumors**
J. P. Peyrat, J. Bonneterre, J. C. Laurent, M. M. Louchez, S. Amrani, B. Leroy-Martin, M. O. Vilain, A. Delobelle and *A. Demaille*	1425	**Presence and characterization of insulin-like growth factor 1 receptors in human benign breast disease**

P. Mack, B. Ahrén, B. Jeppsson, Z. Kan and *S. Bengmark*	1433	**Influence of 2-deoxy-D-glucose and arterial ischaemia on glucose oxidation and growth of liver cancer in the rat**
J. L. Mansi, C. Fisher, E. Wiltshaw, S. MacMillan, M. King and *R. Stuart-Harris*	1439	**A phase I–II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma**
J. Gioanni, J.-L. Fischel, J.-C. Lambert, F. Demard, C. Mazeau, E. Zanghellini, F. Ettore, P. Formento, P. Chauvel, C.-M. Lalanne and *A. Courdi*	1445	**Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment**
P. Hilgard, J. Stekar, R. Voegeli, J. Engel, W. Schumacher, H. Eibl, C. Unger and *M. R. Berger*	1457	**Characterization of the antitumor activity of hexadecylphosphocholine (D 18506)**
T. Mori, M. Shimizu and *T. Iwaguchi*	1463	**Immunological characterization and clinical significance of low mobility cells appearing in the peripheral blood mononuclear cells of cancer patients**
H. Anderson, J. Wagstaff, D. Crowther, R. Swindell, M. J. Lind, J. McGregor, M. S. Timms, D. Brown and *P. Palmer*	1471	**Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer**
B. Marini, R. Bassan and *T. Barbui*	1481	**Therapeutic efficacy of danazol in myelodysplastic syndromes**
E. Rapaport	1491	**Experimental cancer therapy in mice by adenine nucleotides**
A. de Gramont, M. Krulik, J. Cady, B. Lagadec, J.-E. Maisani, J.-P. Loiseau, J.-D. Grange, G. Gonzalez-Canali, B. Demuynck, C. Louvet, J. Seroka, C. Dray and *J. Debray*	1499	**High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer**
S. Einhorn, J.-O. Fernberg, D. Grandér and *R. Lewensohn*	1505	**Interferon exerts a cytotoxic effect on primary human myeloma cells**
T. Kanematsu, Y. Maehara, T. Kusumoto and *K. Sugimachi*	1511	**Sensitivity to six antitumor drugs differs between primary and metastatic liver cancers**
C. Focan, G. Vandermoten, J. Boossy and *D. Schallier*	1515	**Oral etoposide preceding cisplatin in advanced non small cell lung cancer (NSCLC). A phase II study**
L.-M. Ching and *B. C. Baguley*	1521	**Enhancement of *in vitro* cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512)**
Short Communication		
M. R. Law, W. K. Lam and *M. E. Hodson*	1527	**Post-operative intrapleural BCG in lung cancer**
Letters to the Editor		
R. J. C. Slebos, A. de Graeff, N. van Zandwijk, W. J. Mooi, J. L. Bos and *S. Rodenhuis*	1529	**Recurrent breast cancer and an adenocarcinoma of the lung occurring in one patient: c-*myc* oncogene amplification and K-*ras* codon 12 point mutation as tumour markers**
A. Rathmell, P. S. Master and *C. S. Scott*	1531	**Evidence for the non-reactive nature of lymphoid elements in serous effusions from patients with cancer**
Special Article		
J. P. Davignon, J. A. Slack, J. H. Beijnen, W. R. Vezin and *T. J. Schoemaker*	1535	**EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs**
Meeting Abstracts	1539	**Abstracts from the First Annual Meeting of The Danish Society for Cancer Research**
Books Received	1557	
Erratum	1559	
EJCCO Service	i	
Software Survey Section	I	

NUMBER 10, OCTOBER 1988

J. Benard, L. Bettan-Renaud, A. Gavoille, J.-L. Pico, F. Beaujean, M. Lopez and *G. Riou*	1561	***In vitro* chemical eradication of small cell lung cancer: application in autologous bone marrow transplantation**
A. Howell, J. Mackintosh, M. Jones, J. Redford, J. Wagstaff and *R. A. Sellwood*	1567	**The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast**

G. Blomqvist, U. Bagge and *G. Skolnik*	1573	**Arterial occlusion reduces tumour cell lodgement in the rat liver**
R. Labianca, G. Pancera, B. Cesana, M. Clerici, F. Montinari and *G. Luporini*	1579	**Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study**
W. Ruka, L. J. Emrich, D. L. Driscoll and *C. P. Karakousis*	1583	**Tumor size/symptom duration ratio as a prognostic factor in patients with high-grade soft tissue sarcomas**
J. C. Hendrick, J. Collette, S. Claes and *P. Franchimont*	1589	**Epithelial membrane antigen (EMA) distribution in various biological fluids**
G. Cimino, F. lo Coco, C. Cartoni, T. Gallerano, M. Luciani, M. Lopez and *G. de Rossi*	1595	**Immune-deficiency in Hodgkin's disease (HD): a study of patients and healthy relatives in families with multiple cases**
W. J. F. van der Vijgh, D. van Velzen, J. S. E. van der Poort, H. M. M. Schlüper, K. Mross, J. Feijen and *H. M. Pinedo*	1603	**Morphometric study of myocardial changes during doxorubicin-induced cardiomyopathy in mice**
E. Salloum, M. Henry-Amar, B. Caillou, S. Friedman, J.-L. Pico, C. Bayle and *M. Hayat*	1609	**Lymphoblastic lymphoma in adults: a clinicopathological study of 34 cases treated at the Institut Gustave-Roussy**
J. F. Mackintosh, R. A. Cowan, M. Jones, M. Harris, D. P. Deakin and *D. Crowther*	1617	**Prognostic factors in stage I and II high and intermediate grade non-Hodgkin's lymphoma**
S. G. Archer and *B. N. Gray*	1623	**A new reproducible model of hepatic and peritoneal metastases from colonic carcinoma**
J. J. Tjandra, P. J. McLaughlin, I. S. Russell, J. P. Collins and *I. F. C. McKenzie*	1633	**Comparison of mammary serum antigen (MSA) with β_2-microglobulin (β_2M) and carcinoembryonic antigen (CEA) assays in patients with breast cancer**
G. Andry, G. Chantrain, M. van Glabbeke and *P. Dor*	1641	**Papillary and follicular thyroid carcinoma**
A. E. Lykkesfeldt, C. Rose, S. M. Thorpe, I. Laursen, G. Lykkesfeldt and *P. Briand*	1647	**Reversible inhibitory activity of sera from breast cancer patients on oestrogen**
M.-A. Piens, D. Guyotat, E. Archimbaud, C. Plotton, J. Maupas, M. Mojon and *D. Fiere*	1655	**Evaluation of a *Candida* antigen detection test (Cand-Tec™) in the diagnosis of deep candidiasis in neutropenic patients**
O. R. Monge, E. K. Rofstad and *O. Kaalhus*	1661	**Thermochemotherapy *in vivo* of a C3H mouse mammary carcinoma: single fraction heat and drug treatment**
R. Abe, T. Akiyoshi, F. Koba, H. Tsuji and *T. Baba*	1671	**'Two-route chemotherapy' using intra-arterial cisplatin and intravenous sodium thiosulfate, its neutralizing agent, for hepatic malignancies**
Letter to the Editor *A. Thyss, G. Milano, M. Schneider* and *F. Demard*	1675	**Circulating drug levels in patients presenting cardiotoxicity to 5-FU**
Special Article *P. Ebbesen, M. Melbye, J. Suni, G. R. F. Krueger, G. Füst, K. Nagy, A. Horvath, E. Ujhelyi, H. Briem, F. Aiuti, G. Luzi, A. de Rossi, M. C. Sirianni, F. Agius, L. Ayres, W. Magdzik, M. Böttinger, P. C. Frei, M. Karlovac, B. Pocek* and *M. Likar*	1677	**Diffusion of HIV-1 virus into non-habitual categories at risk in European countries**
Announcement	1681	
EJCCO Service	i	
Software Survey Section	I	

NUMBER 11, NOVEMBER 1988

Obituary	1683	
F. Battaglia, G. Scambia, S. Rossi, P. B. Panici, R. Bellantone, G. Polizzi, P. Querzoli, R. Negrini, S. Iacobelli, F. Crucitti and *S. Mancuso*	1685	**Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement**
S. Dumont, D. Hartmann, P. Poindron, F. Oberling, A. Faradji and *J. Bartholeyns*	1691	**Control of the antitumoral activity of human macrophages produced in large amounts in view of adoptive transfer**

F. A. Dorr, J. G. Kuhn, J. Phillips and *D. D. von Hoff*	1699	**Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide**
M. J. McKay and *A. O. Langlands*	1707	**On the yield of new information from the selective requesting of *post mortem* examinations in oncology patients**
S. Noguchi, K. Miyauchi, S. Imaoka, H. Koyama and *T. Iwanaga*	1715	**Comparison of enzyme immunoassay with dextran-coated charcoal method in the determination of progesterone receptor in breast cancer cytosols**
R. Willemze, U. Jager, U. Jehn, P. Stryckmans, J. Bury, S. Suciu, G. Solbu, R. Zittoun, J. Burghouts, B. Löwenberg, J. Abels and *Ch. Cauchie*	1721	**Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study**
M. Numoto	1727	**The same external signal differentially induced the c-myc expression in Burkitt lymphoma and B-lymphoblastoid cell lines**
G. Sava, V. Ceschia and *G. Zabucchi*	1737	**Evidence for host-mediated antitumor effects of lysozyme in mice bearing the MCa mammary carcinoma**
A. M. Ackrill and *G. E. Blair*	1745	**Expression of hamster MHC class I antigens in transformed cells and tumours induced by human adenoviruses**
K. Sue, A. Nakagawara, S. Okuzono, T. Fukushige and *K. Ikeda*	1751	**Combined effects of vitamin E (alpha-tocopherol) and cisplatin on the growth of murine neuroblastoma *in vivo***
W. T. Bellamy, D. S. Alberts and *R. T. Dorr*	1759	**Daily variation in non-protein sulfhydryl levels of human bone marrow**
H. Kr. Kotlar and *T. Sanner*	1763	**Role of T-lymphocytes in production of a cancer-associated protein factor in serum from lung cancer patients**
R. E. Taylor, S. G. Allan, M. A. McIntyre, G. R. Kerr, A. J. Taylor, G. L. Ritchie and *R. C. F. Leonard*	1771	**Influence of therapy on local control and survival in Stage I and II intermediate and high grade non-Hodgkin's lymphoma**
D. B. Smith, G. J. S. Rustin, R. Hitchins, K. D. Bagshawe and *P. Hoskins*	1779	**Single agent activity of methotrexate in advanced non-seminomatous testicular germ cell tumours**
E. Schneider, S. J. Darkin, P. A. Lawson, L.-M. Ching, R. K. Ralph and *B. C. Baguley*	1783	**Cell line selectivity and DNA breakage properties of the antitumour agent *N*-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II**
T. Cerny, A. Pedrazzini, R. A. Joss and *K. W. Brunner*	1791	**Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC)**
Clinical Trials Summaries *S. Thongprasert, K. Klunklin, K. Phornphutkul, O.-A. Prisontarangkul, B. Chaimongkol* and *B. Sivasomboon*	1795	**Phase II study of ifosfamide (Holoxan®) in hepatoma**
Letter to the Editor *O. J. Repelaer van Driel* and *C. J. H. van de Velde*	1797	**Blood transfusion and prognosis in surgical cancer patients**
EJCCO Service	i	
Software Survey Section	I	

NUMBER 12, DECEMBER 1988

Perspectives in Cancer Research *M. R. Price*	1799	**High molecular weight epithelial mucins as markers in breast cancer**
A. P. S. Terblanche, G. Falkson and *L. Matzner*	1805	**The prognostic significance of age in patients with advanced Hodgkin's disease**
R. J. Santen, S. J. Santner, H. A. Harvey, A. Lipton, M. Simmonds, P. D. Feil, E. Manders and *T. S. Davis*	1811	**Marked heterogeneity of aromatase activity in human malignant melanoma tissue**
S. P. Robinson, D. A. Mauel and *V. C. Jordan*	1817	**Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model**
T. Ohkubo, M. Higashigawa, H. Kawasaki, H. Kamiya, M. Sakurai, Y. Kagawa, E. Kakito, K. Sumida and *K. Ooi*	1823	**Sequence-dependent antitumor effect of VP-16 and 1-β-D-arabinofuranosylcytosine in L1210 ascites tumor**

Y. Kikuchi, M. Miyauchi, I. Iwano, T. Kita, K. Oomori and *I. Kizawa*	1829	**Adjuvant effects of prostaglandin D_2 to cisplatin on human ovarian cancer cell growth in nude mice**
O. Mogensen, B. Mogensen, A. Jakobsen and *A. Sell*	1835	**Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operation**
R. Cellerino, D. Tummarello, E. Porfiri, F. Guidi, P. Isidori, M. Raspugli, B. Biscottini and *G. Fatati*	1839	**Non small cell lung cancer (NSCLC). A prospective randomized trial with alternating chemotherapy CEP/MEC' versus no treatment**
R. Bertini and *P. Ghezzi*	1845	**Depression of liver drug metabolism in sarcoma-bearing mice. Evidence for a circulating factor and dissociation from lipolytic activity**
J. Bonneterre, L. Mauriac, B. Weber, H. Roche, P. Fargeot, M. Tubiana-Hulin, M. Sevin, P. Chollet and *P. Cappelaere*	1851	**Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial**
M. J. Goodman, R. D. Bulbrook and *J. W. Moore*	1855	**The distribution of estradiol in the sera of normal Caucasian, Chinese, Filipina, Hawaiian and Japanese women living in Hawaii**
W. Helliger, J. Hofmann, K. Maly, W. Doppler, B.-J. Hermann, W. Höck, B. Puschendorf and *H. Grunicke*	1861	**Differential sensitivity of histone acetylation in nitrogen mustard sensitive and resistant cells. Relation to drug uptake, formation and repair of DNA-interstrand cross-links**
F. Labrie, A. Dupont, M. Giguere, L. Cusan, N. Bergeron, J. Emond, G. Monfette, Y. Lacourciere, H. Boucher and *R. Lachance*	1869	**Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinoma**
A. J. Thody, I. Oliver and *G. V. Sherbet*	1879	**Cytotoxicity of 4-hydroxyanisole and tyrosinase activity in variant cell lines of B16 melanoma**
J. P. van Netten, J. B. Armstrong, S. S. Carlyle, N. L. Goodchild, I. G. Thornton, M. L. Brigden, P. Coy and *C. Fletcher*	1885	**Estrogen receptor distribution in the peripheral, intermediate and central regions of breast cancers**
B. Lathan, V. Diehl, G. M. Clark and *D. D. von Hoff*	1891	**Cytotoxic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine 5-monophosphate (fludarabine, NSC 312887) in a human tumor cloning system**
Clinical Trials Summaries *T. Yoshida, N. Okazaki, M. Yoshino, H. Ohkura, K. Miyamoto* and *Y. Shimada*	1897	**Phase II trial of mitoxantrone in patients with hepatocellular carcinoma**
Sounding Board *J. P. van Netten, J. B. Armstrong, S. J. Carlyle, N. L. Goodchild, I. G. Thornton, M. L. Brigden, P. Coy* and *C. Fletcher*	1899	**Cellular distribution patterns of estrogen receptors in human breast cancer**
Letters to the Editor *G. Schwartsmann, W. J. F. van der Vijgh, I. Klein, C. J. van Groeningen, J. B. Vermorken* and *H. M. Pinedo*	1903	**Pharmacokinetics of Brequinar sodium (NSC 368390; DUP 785) in cerebrospinal fluid**
P. Viens, J.-L. Lagrange, A. Thyss, P. Ayela, M. Frenay and *M. Schneider*	1905	**Brain metastases of lung cancer: excessive toxicity of high dose VP 16 213**
Announcement	1907	**9th International Symposium of the Journal of Steroid Biochemistry**
EJCCO Service	i	
Software Survey Section	I	
Volume Contents and Author Index for Volume 24 (1988)	iii	

SUPPLEMENT 1, 1988

PROPHYLAXIS OF GRAM NEGATIVE INFECTIONS IN NEUTROPENIC PATIENTS

D. van der Waaij	S1	**Selective decontamination of the digestive tract: general principles**
J. E. Karp, J. D. Dick and *W. G. Merz*	S5	**Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient**
D. J. Winston, W. G. Ho, R. P. Gale and *R. E. Champlin*	S15	**Prophylaxis of infection in bone marrow transplants**

P. N. R. Heseltine, D. M. Causey, M. D. Appleman, M. L. Corrado and *J. M. Leedom*	S25	**Norfloxacin in the eradication of enteric infections in AIDS patients**
M. L. Corrado, W. E. Struble and *M. Hesney*	S29	**The tolerability profile of prophylactic norfloxacin in neutropenic patients**
J. Klastersky, S. H. Zinner, T. Calandra, H. Gaya, M. P. Glauser, F. Meunier, M. Rossi, S. C. Schimpff, M. Tattersall, C. Viscoli and the EORTC Antimicrobial Therapy Cooperative Group	S35	**Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials**
J. D. Dick, V. Shull, J. E. Karp and *J. Valentine*	S47	**Bacterial and host factors affecting *Pseudomonas aeruginosa* colonization versus bacteremia in granulocytopenic patients**
D. R. Nalin	S55	**Bacterial resistance to norfloxacin and other newer quinolones: pattern and prospects**
Discussion	S63	

SUPPLEMENT 2, 1988
NEW PERSPECTIVES IN MELANOMA IMMUNOLOGY

F. J. Lejeune and *U. Kleeberg*	S1	**Introduction**
S. Carrel, M. Prade, Ph. Rumke and *F. Lejeune*	S3	**The EORTC Melanoma Group exchange program: a multicenter monoclonal antibody study**
D. J. Ruiter, P. M. Steijlen, W. Bergman and *E. Scheffer*	S15	**Premalignant and borderline melanocytic lesions**
D. J. Ruiter, E.-B. Bröcker, C. Vennegoor and *S. Ferrone*	S23	**Phenotypic heterogeneity of melanoma**
P. C. Hageman, C. Vennegoor, M. A. van der Valk, E. P. van der Esch, J. G. van den Tweel, D. J. Ruiter, S. G. van Duinen and *P. Rümke*	S33	**Reactivity of monoclonal antibody NKI/C-3 directed against a melanoma-associated antigen with formalin-fixed paraffin-embedded normal and tumor tissues**
G. Beckenkamp, H. Schäfer and *D. von Domarus*	S41	**Immunocytochemical parameters in ocular malignant melanoma**
U. R. Kleeberg, A. Loycke, T. Meier, W. Böcker, E.-B. Bröcker, F. Lejeune and *S. Carrel*	S47	**Sensitivity, selectivity and specificity of monoclonal antibodies directed at tumor-associated antigens from metastatic melanoma**
L. Giuffrè, P. Isler, M. Schreyer and *S. Carrel*	S51	**Melanoma-associated differentiation antigens: investigation with monoclonal antibodies**
J. P. Johnson, B. Holzmann, J. M. Lehmann and *G. Riethmüller*	S59	**Characterization of antigens differentially expressed by malignant melanoma and nevocellular nevi**
W. G. Dippold, H. Bernhard, H. P. Dienes and *K.-H. Meyer zum Büschenfelde*	S65	**Treatment of patients with malignant melanoma by monoclonal ganglioside antibodies**
P. von Wussow, L. Spitler, B. Block and *H. Deicher*	S69	**Immunotherapy in patients with advanced malignant melanoma using a monoclonal anti-melanoma antibody ricin A immunotoxin**
S. Matzku, H. Kirchgeßner, E.-B. Bröcker and *W. Tilgen*	S75	**Manipulation of melanoma targeting with monoclonal antibodies: influences on internalization and release**
F. J. Lejeune, E. Macher, U. Kleeberg, P. Rumke, M. Prade, D. Thomas and *S. Suciu*	S81	**An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase III adjuvant study. EORTC protocol 18761**
Short Communications		
C. G. Figdor and *J. E. de Vries*	S91	**Melanoma-associated cellular adhesion molecules (MACAM)**
M. R. M. van den Brink, G. N. P. van Muyen, C. J. Guyt, P. I. Schrier and *D. J. Ruiter*	S93	**Suppression of HLA class II expression in human melanoma cells xenografted to nude mice**